David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
David Ledger, Founder and Medical Director at Varese Group Pty Ltd, shared a post on LinkedIn:
“Bayer just handed the anticoagulation field its first approved Factor XIa inhibitor, anywhere in the world, and it happened in China.
Eikon’s EIK1001 plus pembrolizumab hit 72.4 percent response rate in first-line squamous lung cancer, a number that will draw serious attention ahead of any pivotal readout.
Merck’s sacituzumab tirumotecan cut mortality risk 32 percent versus chemotherapy in endometrial cancer, while pembrolizumab monotherapy stretched median progression-free survival to 38.2 months in the same tumour type with a different biomarker cut.
WuXi AppTec raised full-year guidance again, with nine-month revenue up 38.6 percent, signalling contract research and manufacturing demand remains robust despite geopolitical noise.
Full roundup, all 31 stories, here.”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters
-
Oct 28, 2026, 13:13Michael Cahillane: Three-Buffy-Coat Platelets – Strengthening Blood Supply Resilience